Results for tag: "Monoclonal Antibodies In Veterinary Health"

In the field of animal healthcare, monoclonal antibodies (mAbs) represent a novel class of therapeutics designed to target specific antigens with high specificity. These antibodies are engineered to match the unique markers found on diseases, enabling targeted therapy for a range of conditions in animals, including pets, livestock, and wildlife. The appeal of monoclonal antibodies lies in their ability to offer a more precise treatment option with potentially fewer side effects compared to conventional therapies, such as chemotherapy in cancer treatments or steroids for autoimmune diseases. Veterinary monoclonal antibodies are developed through a biotechnological process similar to that used in human medicine. They are tailored to various species-specific ailments, with a keen focus on diseases prevalent in domestic animals such as cats and dogs. For instance, mAbs have been utilized in the management of chronic pain associated with osteoarthritis in dogs and as a part of the therapeutic regimen for feline asthma. The sector has seen growth due to the increased emphasis on pet care and the advancement of veterinary science, leading to the exploration of mAbs for various applications. Their integration into veterinary health strategies underscores a commitment to enhancing the welfare of animals through innovative medical interventions. Some companies that operate within the monoclonal antibodies in veterinary health market include Zoetis, Boehringer Ingelheim Vetmedica, Merck Animal Health (known as MSD Animal Health outside the United States and Canada), Elanco, and AB Science. These companies are engaged in the research, development, Show Less Read more